Enzon Announces Special Dividend

Enzon Pharmaceuticals, Inc. ( NASDAQ : ENZN ) today announced that its Board of Directors has authorized a special dividend of $2.00 per common share, payable on December 21, 2012 to shareholders of record as of December 10, 2012. 

Alex Denner, Chairman of the Board, commented: "In addition to our ongoing stock buyback program, this special dividend is another step in returning value to shareholders. We have been and will continue to explore options for delivering value." 

BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction

BioCryst Pharmaceuticals, Inc. (BCRX) and privately held Presidio Pharmaceuticals, Inc. today announced the mutual termination of the Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012. Although the original rationale for the merger had merit, the parties determined that terminating the merger was in the best interest of both companies and their respective shareholders at this time.

The termination of the transaction has been approved by the Boards of both companies. In association with the termination, both parties will release each other from all obligations with respect to the proposed transaction. Each company will bear its own legal and transaction fees.

Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Galena Biopharma (GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced two presentations at the 35^th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Poster # P5-18-07 entitled, "Completed SN33 Trial: 60 month follow-up of Early Stage Node Positive HER2 Negative patients with NeuVax(TM) (E75) and sargramostim," will be presented on Friday, December 7, 2012 from 5:00 p.m. to 7:00 p.m. CST during Poster Session 5.

Intellipharmaceutics Announces Results of Initial Phase I Clinical Trial of Controlled-Release Pregabalin and Product Updates

Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced successful results of an initial Phase I clinical trial of a controlled-release pregabalin formulation. We also announced an update to the 2012 goals of our Rexista(TM) abuse-deterrent formulations for oxycodone, and an update to the development activities of our generic version of Focalin XR(R).